Skip to main content

Advertisement

Fig. 3 | Arthritis Research & Therapy

Fig. 3

From: Baseline metabolic profiles of early rheumatoid arthritis patients achieving sustained drug-free remission after initiating treat-to-target tocilizumab, methotrexate, or the combination: insights from systems biology

Fig. 3

Network correlation between transcriptomic (gray nodes), proteomic (orange nodes), and metabolomic (blue nodes) biomarkers in the (a) tocilizumab plus methotrexate, (b) tocilizumab, and (c) methotrexate strategy arms. Only significant transcriptomic–proteomic and proteomic–metabolomic correlations are displayed

Back to article page